3.02
-0.07(-2.27%)
Currency In USD
Address
128 Spring Street
Lexington, MA 02421
United States of America
Phone
857 285 4140
Website
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
June 18, 2021
| Name | Title | Pay | Year Born |
| Dr. Markus F. Renschler M.D. | President, Chief Executive Officer & Director | 718,620 | 1961 |
| Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board | 81,500 | 1962 |
| Mr. David G. Gaiero | Chief Financial Officer & Treasurer | 0 | 1978 |
| Dr. Kevin Mills Ph.D. | Co-Founder | 0 | N/A |
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.